Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DreaMS Extension: Ceralifimod in RRMS
NCT01226745Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Oct 2010
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of ceralifimod in relapsing-remitting multiple sclerosis (RRMS) (6 arms), sponsored by EMD Serono. Primary endpoints: Number of Subjects With Clinically Significant Abnormal Vital Signs at Week 255, Change From Baseline in Forced Expiratory Volume in One Second at Week 255 and 6 more. Started Oct 2010; status: terminated.
02
Drugs
ceralifimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01226745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01226745.